Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy-Induced Cytokine Release Syndrome
Soichiro Minami,Yosuke Kawashima,Yasuhiko Munakata,Masahiro Matsuno,Shuichiro Hara,Yusuke Yamazaki,Tsuyoshi Doman,Shin Saito,Tetsuo Odaka,Takahiro Ogasawara,Hisashi Shimizu,Jun Sugisaka,Tomoiki Aiba,Yukihiro Toi,Shinsuke Yamanda,Yuichiro Kimura,Shunichi Sugawara
DOI: https://doi.org/10.1002/cnr2.2145
Abstract:Background: The expansion of preoperative immunochemotherapy has led to an increase in the number of patients with lung cancer receiving immune checkpoint inhibitors (ICIs). Therefore, oncologists should manage a variety of immune-related adverse events (irAEs). One of the rare, life-threatening, and recently proposed irAEs is cytokine release syndrome (CRS). Although the standard treatment of irAE is systemic administration of steroids, it has been suggested that tocilizumab may be an effective treatment option for CRS. Case: This case describes a 69-year-old man with stage IIIA lung adenocarcinoma who received chemotherapy and nivolumab, which is an ICI, as neoadjuvant immunochemotherapy. After the first administration, the patient developed severe skin rash, fever, and arthralgia. We suspected irAEs and administered systemic steroids. However, fever and arthralgia did not improve, although the skin rash disappeared. These were also significant challenges for surgery. Noting the elevated levels of inflammatory cytokines, we consulted a rheumatologist. Finally, we decided to terminate neoadjuvant therapy after one cycle and administer tocilizumab. Tocilizumab dramatically improved the patient's symptoms and allowed him to undergo radical surgery. Pathological findings revealed that the patient achieved a major pathological response. Conclusion: This indicates the potential effectiveness of early tocilizumab administration for ICI-induced CRS, even in mild cases.